Risk Info Should Be In Ad, Not Attached Label, FDA Says In Bystolic Ad Letter

Putting product labeling at the end of a journal ad "does not mitigate the misleading omission of risk information in the body of the ad," FDA's ad division concludes in a warning letter for Forest Laboratories'Bystolic (nebivolol)